Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

AFQ056

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Long-term use of levodopa (L-dopa) in patients with Parkinson's disease is associated with development of dyskinesia. This study… Expand
Is this relevant?
Highly Cited
2015
Highly Cited
2015
This study investigated the hypothesis that AFQ056 (mavoglurant), a selective metabotropic glutamate receptor 5 antagonist… Expand
Is this relevant?
Highly Cited
2015
Highly Cited
2015
Apart from Huntington's disease, little is known of the genetics of autosomal dominant chorea associated with dystonia. Here we… Expand
Is this relevant?
2015
2015
  • A. Mullard
  • Nature Reviews Drug Discovery
  • 2015
  • Corpus ID: 39513057
The clinical failure of two large mGluR5-antagonist programmes in Fragile X syndrome has forced drug developers to rethink trial… Expand
Is this relevant?
Highly Cited
2013
Highly Cited
2013
AFQ056 is a novel, selective metabotropic glutamate receptor 5 antagonist. This was a 13‐week, double‐blind, placebo‐controlled… Expand
Is this relevant?
2013
2013
The disposition and biotransformation of 14C-radiolabeled mavoglurant were investigated in four healthy male subjects after a… Expand
  • table 1
  • figure 2
  • table 3
  • figure 3
  • table 4
Is this relevant?
Highly Cited
2011
Highly Cited
2011
An antagonist for the metabotropic glutamate receptor may improve symptoms in patients with fragile X syndrome whose FMR1… Expand
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Study objectives were to assess the efficacy, safety, and tolerability of AFQ056 in Parkinson's disease patients with levodopa… Expand
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Fragile X syndrome, the most common form of inherited intellectual disability, is caused by a lack of FMRP, which is the product… Expand
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Overactivity of glutamatergic transmission has been implicated in Parkinson's disease (PD) and levodopa (L-Dopa)-induced… Expand
  • figure 2
  • figure 1
  • figure 3
  • figure 4
Is this relevant?